Genmab A/S has reached the fourth milestone in its daratumumab collaboration with Janssen Biotech, triggering a $10 million payment related to progress in the ongoing Phase III study (“CASTOR” MMY3004).   The Phase III study is evaluating daratumumab in combination with bortezomib and dexamethasone compared to bortezomib and dexamethasone alone for the treatment of relapsed or refractory multiple myeloma. The primary endpoint of the study is progression free survival (PFS).   “...